Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Zibelman

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Urologic Oncology|July 1, 2025
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysisGabriela Gazzoni, Isabella Michelon, Maysa Vilbert, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
Oncotarget|September 15, 2016
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracyPhillip N Gray, Huy Vuong, Pei Tsai, et al.
JCO Clinical Cancer Informatics|January 25, 2021
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal CancerWilliam H Ward, Caitlin R Meeker, Elizabeth Handorf, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
The Journal of Urology|February 4, 2021
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective TrialMatthew Zibelman, Aeen M Asghar, Daniel C Parker, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Urologic Oncology|July 1, 2025
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysisGabriela Gazzoni, Isabella Michelon, Maysa Vilbert, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
Oncotarget|September 15, 2016
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracyPhillip N Gray, Huy Vuong, Pei Tsai, et al.
JCO Clinical Cancer Informatics|January 25, 2021
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal CancerWilliam H Ward, Caitlin R Meeker, Elizabeth Handorf, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
The Journal of Urology|February 4, 2021
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective TrialMatthew Zibelman, Aeen M Asghar, Daniel C Parker, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Pageof 6